This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
DENTSPLY SIRONA Renews Canadian Distribution Agreement
by Zacks Equity Research
DENTSPLY SIRONA Inc. (XRAY), a dental solutions company, recently announced the renewal of an existing distribution agreement with Henry Schein Canada, Inc.
Luminex Gets CE Mark for ARIES Norovirus Assay, Shares Rally
by Zacks Equity Research
Shares of Luminex Corporation (LMNX) gained 1.5% to close at $21.38 after the company announced the receipt of CE-IVD mark for the ARIES Norovirus Assay.
CryoLife Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Leading medical device and tissue processing company, CryoLife, Inc. (CRY) rallied to a new 52-week high of $20.20 on Jun 27, eventually closing a little lower at $19.65.
Express Scripts Gains from Increased Generic Utilization
by Zacks Equity Research
On Jun 27, we issued an updated research report on St. Louis, MO-based pharmacy benefit manager Express Scripts Holding Company (ESRX).
Varian Rides on Oncology and Proton Therapy Businesses
by Zacks Equity Research
On Jun 27, we issued an updated research report on Palo Alto, CA-based Varian Medical Systems Inc. (VAR).
What Drove Becton, Dickinson (BDX) to a New 52-Week High?
by Zacks Equity Research
Share price of Becton, Dickinson and Company (BDX) , based in Franklin Lakes, NJ, Becton, scaled a new 52-week high of $196.01 on Jun 27.
Quintiles' (Q) OCE Software to Simplify Commercial Functions
by Zacks Equity Research
QuintilesIMS (Q) announced the general availability of Orchestrated Customer Engagement (OCE) software to streamline pharmaceutical commercial functions.
Medidata (MDSO), inVentiv Enter Into Multi-Year Partnership
by Zacks Equity Research
Medidata Solutions Inc. (MDSO) recently announced that it has entered into a multi-year partnership with inVentiv Health, a leading biopharmaceutical professional services company.
Merit Medical Embosphere Gets FDA de novo Classification
by Zacks Equity Research
Merit Medical Systems, Inc. (MMSI) recently announced the receipt of 513(f)(2) (de novo) classification for Embosphere Microspheres from the FDA to expand its indication in the prostatic artery embolization (PAE) space.
ConforMIS (CFMS) Gets FDA Approval for iTotal Hip System
by Zacks Equity Research
Medical technology company, ConforMIS, Inc. (CFMS) recently announced the receipt of FDA 510(k) clearance for its primary iTotal Hip replacement system.